Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Non-drug and non-surgical low back pain treatments are highly cost-effective options (opens in a new tab)

news-medical.net · 2026-10-27

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of five check out. Two claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedNon-drug and non-surgical treatments for low back pain are cost-effective interventions, according to a study published in PLOS Medicine.View evidenceHide evidence

Why this verdict

The abstract-level paper profile supports that most guideline-recommended non-pharmacological, non-surgical interventions appeared cost-effective versus usual care, and that some were potentially cost-saving. The headline wording presents the whole class of non-drug/non-surgical treatments as cost-effective without the paper’s qualifiers about 'most' interventions, heterogeneity, and high-income-country evidence, so the headline outruns the more nuanced evidence.

1

Study evidence

Most guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain were reported as cost-effective at a £20,000 per QALY willingness-to-pay threshold compared with usual care.

“We searched 10 electronic databases ... from inception to 9th of February 2026 for cost-effectiveness studies”
Claim 2 of 5Not coveredThe study reviewed 20 studies conducted between 2005 and 2026 with 14,884 participants, comparing non-pharmacological and non-surgical interventions such as yoga, acupuncture, massage, psychological therapy, spinal manipulation, exercise, and diet plans against first-contact care or no treatment.View evidenceHide evidence

As stated20 studies; 14,884 participants

Why this verdict

The profile supports a systematic review including 20 studies published from 2005–2026, but the abstract-level profile does not verify the stated 14,884 participant count, the full intervention list as written, or the comparator phrasing of 'first-contact care or no treatment.' It also describes studies as published in 2005–2026 rather than necessarily conducted in that interval.

1

Study evidence

Most guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain were reported as cost-effective at a £20,000 per QALY willingness-to-pay threshold compared with usual care.

“We searched 10 electronic databases ... from inception to 9th of February 2026 for cost-effectiveness studies”
Claim 3 of 5Not coveredTwo multimodal interventions—advice plus graded workplace activity, and diet plus physical activity—were reported as more cost-effective than usual care at a willingness-to-pay threshold of £20,000.View evidenceHide evidence

As stated£20,000 willingness-to-pay threshold

Why this verdict

The profile supports that most interventions were cost-effective at a £20,000 per QALY willingness-to-pay threshold, but it does not verify at abstract depth the two specific multimodal interventions named—advice plus graded workplace activity and diet plus physical activity—or their specific cost-effectiveness results.

1

Study evidence

Most guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain were reported as cost-effective at a £20,000 per QALY willingness-to-pay threshold compared with usual care.

“We searched 10 electronic databases ... from inception to 9th of February 2026 for cost-effectiveness studies”
Claim 4 of 5SupportedThe authors found that yoga, cognitive behavioral therapy, self-management support, fear reduction education, and mindfulness stress reduction could reduce health care costs and improve outcomes compared with usual care.View evidenceHide evidence

Why this verdict

The paper profile states that several interventions, including approaches targeting fear/stress reduction, self-management support, yoga, acupuncture, and cognitive/cognitive-therapy approaches, were reported as potentially cost-saving—both more effective and less costly than usual care—from healthcare, societal, and payer perspectives. The story’s wording is broadly consistent, though the abstract-level profile does not provide intervention-specific numeric estimates.

1

Study evidence

Most guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain were reported as cost-effective at a £20,000 per QALY willingness-to-pay threshold compared with usual care.

“We searched 10 electronic databases ... from inception to 9th of February 2026 for cost-effectiveness studies”
2

Study evidence

The review pre-specified and extracted multiple direct cost categories (total, interventional, health service use, community services, out-of-pocket) and indirect costs (e.g., lost wages, lost productivity, absenteeism) as secondary outcomes and presented these data in tables and qualitative synthesis across included studies.

“Secondary outcomes were direct costs (total, interventional, health service use, community services and out-of-pocket costs) and indirect costs (e.g., lost wages, lost productivity, absenteeism).”
Claim 5 of 5SupportedThe article says all included studies were from high-income countries and that differences in how cost-effectiveness was measured limit direct comparison across studies, though the authors suggest broader access to these interventions could benefit patients with low back pain.View evidenceHide evidence

Why this verdict

The profile supports that all included evidence came from high-income countries, that heterogeneity in interventions, populations, study designs, and economic perspectives limits generalisability and comparison, and that the authors conclude improved access to and implementation of effective interventions is warranted.

1

Study evidence

Most guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain were reported as cost-effective at a £20,000 per QALY willingness-to-pay threshold compared with usual care.

“We searched 10 electronic databases ... from inception to 9th of February 2026 for cost-effectiveness studies”
2

Study evidence

Methodological quality appraisal was performed using the CHEC checklist for trial-based economic evaluations and the Philips checklist for modelling studies.

“We assessed methodological quality using the Consensus Health Economics Criteria (CHEC) checklist for within-trial economic evaluations or the Philips checklist for modelling studies.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The review also extracted and qualitatively synthesised secondary direct and indirect cost categories, including health service use, community services, out-of-pocket costs, lost wages, productivity, and absenteeism.

    The story mentions healthcare costs generally but does not reflect the paper’s secondary cost-component analysis or the distinction between direct and indirect cost categories.

    From Systematic review of economic evaluations (within-trial and modelling)

6 things the story did carry across
  • The paper is a registered systematic review of economic evaluations of guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain versus usual care, using cost per QALY converted to 2024 GBP as the primary outcome.
  • The review included 20 studies, comprising 17 within-trial economic evaluations and 3 modelling studies, identified through searches of 10 databases to 9 February 2026.
  • The main finding was that most, not necessarily all, guideline-recommended non-pharmacological, non-surgical interventions were reported as cost-effective at a £20,000 per QALY threshold compared with usual care.
  • Several interventions—especially fear/stress reduction approaches, self-management support, and some clinician-delivered therapies such as yoga, acupuncture, and cognitive therapy—were reported as potentially cost-saving, meaning both more effective and less costly than usual care.
  • The evidence base was heterogeneous in interventions, populations, economic perspectives, and study designs, and the synthesis was qualitative/tabular rather than a pooled meta-analysis.
  • All included studies came from high-income countries, limiting generalisability to low- and middle-income settings.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCritically appraise and summarise evidence on the cost-effectiveness (cost/QALY) of guideline-recommended non-pharmacological, non-surgical interventions for managing non-specific low back pain, compared with usual care.Systematic review of economic evaluationsExpand

In plain English

Registered systematic review (PROSPERO CRD42024510270) synthesising cost-effectiveness (cost per QALY, converted to 2024 GBP) of guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain versus usual care. Searches of 10 databases to 9 Feb 2026 identified 20 studies (17 within-trial economic evaluations, 3 modelling studies). Most interventions were reported as cost-effective at a £20,000 willingness-to-pay threshold; several interventions (including approaches to reduce fear/stress, self-management support, yoga, acupuncture, cognitive therapy) were reported as potentially cost-saving. All included evidence derived from high-income countries and the body of literature was heterogeneous.

Key findings

  • Most guideline-recommended non-pharmacological, non-surgical interventions for non-specific low back pain were reported as cost-effective at a £20,000 per QALY willingness-to-pay threshold compared with usual care.
  • Several interventions—those aiming to reduce fear and stress, self-management support interventions, and some clinician-delivered therapies (e.g., yoga, acupuncture, cognitive therapy)—were reported as potentially cost-saving (both more effective and less costly than usual care) from healthcare, societal and payer perspectives.
“We searched 10 electronic databases ... from inception to 9th of February 2026 for cost-effectiveness studies”
What this piece can’t prove
  • Substantial heterogeneity across included studies in interventions, populations (acute/subacute/chronic), economic perspectives, and study designs.
  • All included evidence came from high-income countries; limited or no evidence from low- and middle-income countries.
  • Review relied on qualitative/tabular synthesis; no quantitative meta-analysis of cost-effectiveness estimates was reported.
  • Variation in methodological quality across included studies (assessed with CHEC and Philips checklists) may affect confidence in some findings.
2secondary dataSummarise evidence on costs (direct and indirect; multiple cost categories and perspectives) of guideline-recommended interventions for low back pain.Systematic review of economic evaluations (within-trial and modelling)Expand

In plain English

The systematic review extracted and synthesised secondary cost outcomes (direct costs: total, interventional, health service use, community services, out-of-pocket; and indirect costs: lost wages/productivity/absenteeism) from economic evaluations of guideline-recommended, non-pharmacological, non-surgical interventions for non-specific low back pain versus usual care. These cost components were tabulated and qualitatively summarised across 20 included studies (17 within-trial economic evaluations, 3 modelling studies). The review reports that many interventions were cost-effective at a £20,000/QALY threshold and that some interventions (notably those targeting fear/stress reduction, self-management support, and certain clinician-delivered therapies such as yoga, acupuncture, and cognitive therapy) were potentially cost-saving from healthcare, societal and payer perspectives, being both more effective and less costly than usual care. All included evidence comes from high-income countries and the synthesis is heterogeneous.

Key findings

  • The review pre-specified and extracted multiple direct cost categories (total, interventional, health service use, community services, out-of-pocket) and indirect costs (e.g., lost wages, lost productivity, absenteeism) as secondary outcomes and presented these data in tables and qualitative synthesis across included studies.
  • Several non-pharmacological, non-surgical interventions (including approaches targeting fear/stress reduction and self-management, and clinician-delivered therapies such as yoga, acupuncture and cognitive therapy) were reported as potentially cost-saving from healthcare, societal and payer perspectives, being both more effective and less costly than usual care.
“Secondary outcomes were direct costs (total, interventional, health service use, community services and out-of-pocket costs) and indirect costs (e.g., lost wages, lost productivity, absenteeism).”
What this piece can’t prove
  • Included evidence is heterogeneous in interventions, populations, and study designs (within-trial and modelling).
  • All evidence reported in the review abstract originates from high-income countries; evidence from low- and middle-income countries is limited per the authors.

1 further detail could not be confirmed from the summary.

3secondary dataAssess methodological quality of included economic evaluations using CHEC (within-trial) and Philips (modelling) checklists, and describe key evidence gaps (e.g., LMICs, heterogeneity).Quality appraisal using CHEC and Philips checklistsExpand

In plain English

The review conducted a structured methodological quality appraisal of included economic evaluations, using the Consensus Health Economics Criteria (CHEC) checklist for within-trial economic evaluations and the Philips checklist for decision-analytic modelling studies. These tools were applied across 17 within-trial and 3 modelling studies. The abstract does not report the detailed results, domain-level ratings, or scoring from those checklists.

Key findings

  • Methodological quality appraisal was performed using the CHEC checklist for trial-based economic evaluations and the Philips checklist for modelling studies.
  • The review identifies a heterogeneous evidence base limited to high-income countries, with limited evidence from low- and middle-income countries noted as an evidence gap.
“We assessed methodological quality using the Consensus Health Economics Criteria (CHEC) checklist for within-trial economic evaluations or the Philips checklist for modelling studies.”
What this piece can’t prove
  • Abstract does not present the outcomes of the CHEC or Philips assessments (no scores, domain-level ratings, or summary judgments).

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Cost-effectiveness of recommended interventions for managing low back pain: A systematic review

PLOS Medicine · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 37 candidate papers

Selected

Cost-effectiveness of recommended interventions for managing low back pain: A systematic review

PLOS Medicine · 2026 · Crossref

Source (opens in a new tab)

And 31 more candidates considered.